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CONVENTIONAL insulins contain several impurities such as proinsulin,
C-peptide, polymers of insulin (Steiner et al, 1968) and other pancreatic peptides
(Bloom et al, 1976). All are immunogenic (Schlichtkrull et al, 1972) and may lead
to the development of insulin-binding antibodies in patients using insulin prepara-
tions containing them. As a result, some patients develop local skin sensitivity,
lipoatrophy or lipohypertrophy at the site of insulin injection. A few develop
resistance to insulin and require very large daily doses of insulin to control their
diabetes.
Highly purified insulin preparations are now available (Montgomery, 1977).
They contain less impurities and have been reported to cause less complications
(Bruni et al, 1973). In order to assess their effectiveness, two groups of patients
have been studied. Thirty-seven patients were changed electively from conventional
beef insulin to highly purified pork insulin, and 16 patients with juvenile onset
diabetes were treated with highly purified pork insulin from the time of diagnosis.
PATIENTS
The patients all attend the Diabetes Clinic of the Royal Victoria Hospital,
Belfast. Those transferred to highly purified pork insulin were selected because
of poor control of their diabetes, high dose of beef insulin, early microvascular
changes or evidence of local reactions to beef insulin such as skin sensitivity,
lipoatrophy or lipohypertrophy.
At intervals during the six months before transfer to highly purified insulin,
daily insulin dose, 2 to 3 hour post-prandial plasma glucose, body weight and
dietary intake were recorded for each patient. These continued to be recorded
during the follow-up period of 6 to 12 months. The patients were asked to report
any hypoglycaemic attacks which occurred during the period of study. All were
admitted to hospital initially because of reported concern about severe hypo-
glycaemic reactions following transfer to highly purified insulin (Asplin and
Hartog, 1976). They were changed either to Leo Neutral and Leo Retard
(Nordisk) or to Actrapid MC and Monotard MC (Novo). These patients were
divided into three sub-groups depending on their mean daily dose of insulin
during the six months before changeover (Table 1).
The patients treated with highly purified insulin from the time of diagnosis
had daily insulin dose, 2 to 3 hour post-prandial plasma glucose and body weight
recorded during a follow-up period of six months. These were compared with
the results for a similar group of patients, started on conventional insulin five
years ago, who were matched for age, sex, body weight and dietary intake.
44TABLE 1: PATIENTS CHANGED FROM CONVENTIONAL BEEF INSULIN TO
HIGHLY PURIFIED PORK INSULIN WITH SUB-GROUPS ACCORDING TO
THEIR MEAN DAILY DOSE OF INSULIN.
Mean daily Mean Number
insulin dose Number Mean age ofyears
prior to of ±S.E.M. diabetes
Sub-Group changeover patients in years ±S.E.M.
A 40 units orless 10 47.7±+5.1 17.4±+3.5
B 41-80 units 17 39.2±+5.2 8.9±+ 1.6
C More than 80 units 10 28.7±+-4.7 11.8±+3.1
RESULTS
The effect on daily insulin dose of changing to highly purified pork insulin is
shown in Fig. 1. There were marked variations within each sub-group. In sub-
group A seven patients showed changes of less than 10 per cent in daily insulin
dose after transfer to highly purified insulin. The other three patients showed a
rise of more than 10 per cent. In sub-group B eight patients showed a change of
less than 10 per cent, four an increase of more than 10 per cent, and five a
decrease of more than 10 per cent. In sub-group C four patients showed a change
of less than 10 per cent, one an increase of more than 10 per cent, and five a
decrease of more than 10 per cent. One patient in this sub-group showed a decrease
of 79 per cent in daily insulin dose one month after changing to highly purified
insulin. This was maintained during the follow-up period.
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DAILY INSULIN DOSE BEFORE AND AFTER
CHANGEOVER TO HIGHLY PURIFIED INSULIN (*P<0.05). NUMBERS IN
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INo significant change in dietary intake occurred in any of the sub-groups,
which is reflected by the absence of any major change in body weight (Fig. 2).
Degree of diabetic control is difficult to assess. Figure 3 shows mean 2 to 3 hour
post-prandial plasma glucose of the three sub-groups. These were in the 10-15
mmol/l range before transfer and are disappointingly high, but despite increased
efforts to improve: control after changing to highly purified insulin, plasma glucose
levels did not change significantly in sub-groups A and C. There was a transient
improvement in siub-group B which was not associated with any significant change
in insulin dose. No increase in clinical hypoglycaemia attacks occurred after
changeover to highly purified insulin. Three patients in this group with local skin
sensitivity to conventional insulin showed no sensitivity with highly purified insulin.
Six other patients with lipoatrophy or lipohypertrophy showed improvement when
changed to a purified preparation.
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FIGURE 2: MEAN ±S.E.M. BODY WEIGHT BEFORE AND AFTER CHANGE-
OVER TO HIGHLY PURIFIED INSULIN. NUMBERS IN COLUMNS INDICATE
NUMBER OF PATIENTS REPRESENTED.
The daily insulin dose in the patients started on highly purified insulin at the
time of diagnosis was slightly higher but not significantly different from that in
the patients on conventional insulin. However, only those on highly purified insulin
showed a fall in daily insulin dose during the follow-up period (Table 2). Dietary
intake and body weight showed no change in -either group. There was a significant
fall in 2 hour post-prandial plasma glucose in the group on highly purified insulin
but not in those on conventional insulin.
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FIGURE 3: MEAN ±S.E.M. 2 TO 3 HOUR POST-PRANDIAL PLASMA
GLUCOSE BEFORE AND AFTER CHANGEOVER TO HIGHLY PURIFIED
INSULIN (*P<0.05). NUMBERS IN COLUMNS INDICATE NUMBER OF
PATIENTS REPRESENTED.
TABLE 2: MEAN +4S.E.M. DAILY INSULIN DOSE IN UNITS (PURIFIED
AND CONVENTIONAL) IN PATIENTS WITH JUVENILE ONSET DIABETES
(*p<0.05).
Type One month Three months Six months
of after starting after starting after starting
insulin insulin insulin insulin
Highlypurified 40.8±4.0 35.5±3.2* 31.1±3.2*
Conventional 31.6+2.6 32.8 ±3.3 34.0+4.2
DISCUSSION
With the advent of highly purified insulins it has become important to decide
which patients should receive them. These results are similar to those from many
other centres in showing that patients with local skin sensitivity, lipoatrophy or
lipohypertrophy on conventional insulin are much improved on highly purified
insulin. Patients on very high doses of conventional insulin, usually due to the
presence of high titres of insulin-binding antibodies, also benefit by getting a
substantial reduction in daily insulin dose. However, for the majority of patients
there is either no reduction or only a modest reduction in insulin dosage. Further-
47more, no improvement in their diabetic control was observed so that it is unlikely
that the diabetic who is well or moderately controlled on conventional insulin will
gain any therapeutic benefit from changing to a highly purified preparation.
Insulins from both Danish manufacturers were used in this study and no important
differences were observed between them.
The group of juvenile onset diabetics started on conventional insulin showed
no change in insulin dose after six months. However, after five years, nine of the
patients, in whom comparison was valid, showed a very marked rise from a mean
of 31.8 to 50 units/day in the absence of change in weight, dietary intake or 2 to
3 hour post-prandial plasma glucose. Information on long-term follow-up of the
patients on highly purified insulin is not available, but Andreani et al (1974)
showed that there was no increase in insulin dose up to two years with these less
immunogenic preparations. It would therefore seem reasonable to use these
insulins in patients receiving treatment for the first time. Whether this will result
in any improvement in the long-term complications of diabetes remains to be seen.
SUMMARY
Clinical experience with the new insulins in two groups of patients is described.
In a group of 37 patients, changed electively from conventional beef insulin to
highly purified pork insulin, only those on more than 80 units/day of beef insulin
showed a marked fall in insulin dosage after changeover. This fall was not main-
tained up to one year in the majority of patients. There was no improvement in
diabetic control after changeover, but marked improvement in local reactions to
insulin did occur. Sixteen patients with juvenile onset diabetes were treated with
highly purified pork insulin from the time of diagnosis. There was no significant
difference in insulin dosage during the first six months of treatment compared with
that in a similar group of patients started on conventional insulin five years ago.
Those on conventional insulin showed a marked rise in insulin dosage after five
years. Information on long-term follow-up of those on highly purified insulin is
not available. Indications for the use of the new insulins are discussed.
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